子宫内膜癌错配修复检测的常规知情同意:综述与伦理分析
该综述检索PubMed和CINAHL至2021年9月,纳入16篇关于林奇综合征风险患者错配修复肿瘤检测知情同意的文章,无一篇专门针对子宫内膜癌。现有数据提示常规检测前知情同意不常见,部分决策辅助工具可改善患者知识和满意度。作者基于现有数据和伦理最佳实践,推荐将计划的内膜癌错配修复检测 routinely 与患者口头讨论或写入手术同意文件。
要点
- 纳入16篇文章,均非专门针对子宫内膜癌的错配修复检测知情同意。
- 现有数据提示肿瘤检测前常规知情同意不常见,决策辅助工具可改善患者知识和满意度。
- 作者推荐将计划的内膜癌错配修复检测常规口头讨论或写入手术同意文件。
核心结论
- 基于现有数据和当代伦理最佳实践,作者推荐将计划的内膜癌错配修复检测常规与患者口头讨论或写入手术同意文件。
研究设计与样本
- 综述与伦理分析,检索PubMed和CINAHL数据库至2021年9月,纳入16篇报告林奇综合征风险患者错配修复肿瘤检测知情同意的文章,并通过参考文献补充文献。
主要发现
- 16篇文章符合纳入标准,无一篇专门涉及子宫内膜癌的错配修复检测。
- 除两项研究外,其余研究均发表于帕博利珠单抗获批用于治疗错配修复缺陷肿瘤之前。
- 有限数据提示肿瘤检测前常规知情同意不常见,但若干决策辅助工具改善了患者决定是否进行肿瘤检测前的知识和满意度。
- 既往伦理分析引用临床效用、潜在胚系影响和后勤因素来提出知情同意实践建议,其最终推荐各不相同,但所有分析在涉及子宫内膜癌患者当代临床护理的论证中均存在显著缺陷。
关键数值与推荐
- 作者推荐将计划的内膜癌错配修复检测常规与患者口头讨论或写入手术同意文件。
临床怎么用
- 作者推荐将计划的内膜癌错配修复检测常规与患者口头讨论或写入手术同意文件。
局限性
- 16篇文章中无一篇专门涉及子宫内膜癌的错配修复检测。
- 除两项研究外,其余研究均发表于帕博利珠单抗获批用于治疗错配修复缺陷肿瘤之前。
- 现有数据有限。
- 既往伦理分析在涉及子宫内膜癌患者当代临床护理的论证中均存在显著缺陷。
- 需要当前数据来评估潜在知情同意策略对肿瘤检测的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review available data regarding consent for tumor testing for mismatch repair (MMR), and to make recommendation for ethical best practices based on synthesis of contemporary data and ethical principles. METHODS: PubMed and CINAHL databases were searched through September 2021; articles reporting on consent for MMR tumor testing for patients at risk for Lynch Syndrome were abstracted. Additional articles were identified through review of references. Key data and ethical principles were extracted, summarized, and analyzed in the context of contemporary clinical practice. RESULTS: 16 articles met inclusion criteria for this review, none of which specifically related to MMR testing for endometrial cancers. All but two studies were published prior to the approval of pembrolizumab for treatment of MMR-deficient tumors. Scant available data suggest that routine consent prior to tumor testing is uncommon; however, several decision aids improved patient knowledge and satisfaction prior to deciding whether to proceed with tumor testing. Previous ethical analyses invoke clinical utility, potential germline implications, and logistical factors in making recommendations regarding consent practices. These analyses varied in their final recommendations; however, all had significant deficits in their arguments related to contemporary clinical care for patients with endometrial cancer. CONCLUSION: Current data are needed to assess the impact of potential consent strategies for tumor testing. Based on available data, and consistent with contemporary ethical best practices, we recommend that planned MMR testing of endometrial cancers be discussed routinely with patients verbally or in surgical consent documents.
引用
- DeMari JA, Shalowitz DI. Routine informed consent for mismatch repair testing in endometrial cancers: Review and ethical analysis. Gynecol Oncol. 2022. PMID: 35953317. doi:10.1016/j.ygyno.2022.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。